Aspirin for Colorectal Cancer Prevention: Age Matters

Imad Shureiqi

doi:10.1158/1940-6207.CAPR-22-0176

Aspirin for Colorectal Cancer Prevention: Age Matters

Cancer Prev Res (Phila). 2022 Sep 1;15(9):565-567. doi: 10.1158/1940-6207.CAPR-22-0176.

Author

Imad Shureiqi^{1

2}

Affiliations

¹ Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.
² Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

PMID: 36047054
DOI: 10.1158/1940-6207.CAPR-22-0176

Abstract

Further data from the Aspirin in Reducing Events in the Elderly (ASPREE) trial heightens the concern regarding aspirin use for colorectal cancer prevention in elderly subjects. A 95-variant colorectal cancer polygenic risk score (PRS) failed to identify a subset of elderly individuals who could have benefited from aspirin preventive activity. Further research to define predictive biomarkers of aspirin preventive activity is needed. Meanwhile, the use of aspirin for colorectal cancer prevention in the elderly becomes more questionable. See Cancer Prev Res 15(7):447-53.

Publication types

Editorial
Comment

MeSH terms

Aged
Aspirin* / therapeutic use
Colorectal Neoplasms* / prevention & control
Double-Blind Method
Genetic Predisposition to Disease
Humans

Substances

Aspirin